SCHEMBL30830775

SCHEMBL30830775

CN1C[C@H](Nc2cnn(C)c(=O)c2Cl)C[C@H](c2ccc(CN3CCN(c4cc5c(cc4F)C(=O)N(C4CCC(=O)NC4=O)C5=O)CC3)cc2)C1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 4/20 0.51
▸ KAT2B Q92831 16/20 0.50
▸ BRD9 Q9H8M2 3/20 0.50
▸ DDB1 Q16531 3/20 0.44
▸ IKZF3 Q9UKT9 3/20 0.44
▸ BRD1 O95696 1/20 0.40
▸ ACHE P22303 1/20 0.40
▸ BRPF1 P55201 1/20 0.40
▸ BPTF Q12830 1/20 0.40
▸ KAT2A Q92830 1/20 0.40
▸ BRD7 Q9NPI1 1/20 0.40
▸ BAZ2B Q9UIF8 1/20 0.40
▸ BRPF3 Q9ULD4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830669 0.94 CRBN (0.51) CRBNKAT2BBRD9DDB1IKZF3
SCHEMBL30830919 0.93 CRBN (0.50) CRBNKAT2BBRD9DDB1IKZF3
SCHEMBL30830747 0.90 KAT2B (0.51) CRBNKAT2BBRD9DDB1IKZF3
SCHEMBL30830529 0.88 KAT2B (0.49) KAT2BBRD9
SCHEMBL30830602 0.87 KAT2B (0.55) CRBNKAT2BBRD9BRD1ACHE
SCHEMBL30830885 0.87 KAT2B (0.55) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830642 0.84 PLK4 (0.46) CRBNKAT2BBRD9DDB1IKZF3
SCHEMBL30830707 0.83 KAT2B (0.51) CRBNKAT2BBRD9DDB1IKZF3
SCHEMBL30830574 0.83 IKZF2 (0.49) CRBNKAT2BBRD9IKZF3
SCHEMBL30831023 0.82 KAT2B (0.55) KAT2BBRD9BPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback